Results 1 to 10 of about 33,385 (252)
Frontiers in Pharmacology, 2021 Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj +1 more source
Haematologica, 2021 Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment.
Joshua N. Gustine +18 more
doaj +1 more source
Molecules, 2023 Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun +7 more
doaj +1 more source
Pathology and Oncology Research, 2022 Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse.
Ferenc Takács +19 more
doaj +1 more source
Haematologica, 2020 The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms
Damien Blez +10 more
doaj +1 more source
Cancer Medicine, 2022 Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy
Yuchen Zhang +21 more
doaj +1 more source
Ibrutinib is not an effective drug in primografts of TCF3-PBX1
Translational Oncology, 2020 Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-
Cesca van de Ven +4 more
doaj +1 more source
CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
Cell Death Discovery, 2022 Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD).
Viktoria Fuhr +7 more
doaj +1 more source
Ibrutinib-related uveitis: A case series
American Journal of Ophthalmology Case Reports, 2022 Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu +4 more
doaj +1 more source
Journal of Neuroinflammation, 2018 Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam +8 more
doaj +1 more source